Treatment News

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News

March 29, 2013
Guidelines Issued for Health Departments to Aid in Linkage and Retention
A think tank has issued recommendations to health departments on how to work with health providers to keep people with HIV from dropping out of care.
March 28, 2013
Pre-Exposure Prophylaxis is Cost-Effective in Some Settings
Pre-exposure prophylaxis, which is when people at high risk of HIV take antiretrovirals as a means of lowering that risk, is cost-effective in some settings.  
March 27, 2013
HIV Prevention Through Sexual Agreements Between Gay Men in Couples
While a majority of gay couples appear to work out agreements on allowable sexual behavior outside the relationship, only about half honor the agreement. 
Each Step of the 'Treatment Cascade' May Not Depend on the Other
Recent dire estimates about the HIV "treatment cascade" may not be as great as previously suspected.
March 26, 2013
Tenofovir-Laced Vaginal Ring Protects Monkeys Against Simian HIV
An intravaginal ring infused with the HIV antiretroviral tenofovir protected six out of six macaque monkeys from repeated exposures to simian HIV.
HIV Tests Are Needed Much More Frequently Than the CDC Advises
Significantly raising the frequency of HIV tests would benefit both high- and low-risk groups and prove cost-effective as well.
March 25, 2013
Low CD4s, Not Viral Load, Increase Risk of Non-AIDS Diseases for Those Off Treatment
People with untreated HIV whose CD4s drop below 350 have more than twice the risk of developing serious non-AIDS diseases as those with levels above 500.
‘Test-And-Treat’ Would Slow HIV Spread, Improve Health Outcomes, but Raise Drug Resistance
Wide HIV testing and early treatment woul lower HIV transmission, AIDS and death rates, but double the rate of multidrug resistance (MDR) to antiretrovirals.
March 22, 2013
Advances in Gene Therapies That Act Like Fusion Inhibitors
Two new gene therapy studies further the hopes that scientists may develop widely replicable methods to control HIV through stem cell modification.
Well-Controlled HIV May Mean No Increased Risk of Death
Successfully controlling HIV and keeping CD4 levels high may reduce the risk of death to that of the general population.
March 21, 2013
Another Study Finds Gay Black Men at Higher HIV Risk Despite Fewer Partners
Gay black men have a higher risk of HIV infection than the general gay population, irrespective of number of sexual partners, injection drug use or age.
Barring Drug Felons From Food Stamps Puts Them at Risk of HIV
Bans against convicted drug felons receiving food stamps or cash assistance may send women into prostitution, raising their risk of contracting HIV.
March 20, 2013
Incivek Improves Outcome and Halves Treatment Time for Hep C in HIV-Positive Men
Adding Incivek to pegylated interferon and ribavirin doubles the cure rate and cuts in half the treatment time for acute hepatitis C among HIV-positive men.
High Community Viral Load a Possible Driver of African HIV Epidemic
The average viral load of those off HIV drugs in sub-Saharan Africa is four times that of North America, which possibly drives the severity of Africa's epidemic.
March 19, 2013
HIV Rates Elevated Among Heterosexuals in Poor Urban Communities
A recent Centers for Disease Control and Prevention  survey of poor urban communities found a high prevalence of HIV among heterosexuals.
March 18, 2013
Interferon-Free Hep C Regimen Cures 95% of First-Time Treaters
The hep C antiviral ABT-450, combined with ribavirin and ABT-072 or ABT-333, yielded cure rates as high as 95 percent in treatment-naive study participants.
14 French People With HIV Advance 'Functional Cure'
Fourteen French adults treated within two months of infection maintain undetectable virus levels after stopping antiretroviral (ARV) therapy.
People With HIV in Care Smoke at Twice the Rate of Those Without
Forty-two percent of people with HIV in care are regular smokers, a rate twice that of the general population.
No Change in Rates of Transmitted Drug-Resistant HIV
The rate of drug-resistant HIV transmitted among newly diagnosed people has remained constant at about one in six cases.
March 14, 2013
Factors Associated With Poor Physical Function in Middle Aged Positive People
Impaired physical function in middle aged people living with HIV are associated with low levels of muscle mass, bone mineral density and insulin levels.
Gay Urbanites More Aware of Their HIV Status, but Prevalence Holds Steady
Urban gay and bisexual men’s awareness of their HIV status has increased, but the prevalence of the virus remains stable among this population. 
March 13, 2013
Bee Venom: The Next Anti-HIV Agent? A Proof-of-Concept Study Says Yes
Nanoparticles filled with a toxin called melittin that’s found in bee venom can destroy HIV and have a benign effect on surrounding cells.
Long-Acting PrEP Injection Prevents Anal Simian HIV Transmission
A long-acting, injectable version of the antiretroviral dolutegravir prevented rectal transmission of simian HIV (SHIV) in eight macaques.
Circumcision May Not Protect White U.K. Gay Men From HIV
A survey of white, British men suggests that circumcision offers no protection against HIV transmission for the top in anal sex between men.
100% Cure Rate for Hep C With Sofosbuvir, Ledipasvir Combo Therapy
An all-oral combination therapy of sofosbuvir, ledipasvir and ribavirin boasts a 100 percent cure rate among people with hepatitis C virus.
March 11, 2013
Young Gay Men’s PrEP Study Shows Feasibility and Challenges
A small study of pre-exposure prophylaxis (PrEP) among young gay men in Chicago found low levels of adherence.
Merck’s Non-Nuke MK-1439 Shows Antiviral Activity, Is Safe and Well Tolerated
Merck’s investigatory non-nuke MK-1439 proved safe and well tolerated—and it displayed robust antiviral activity in a small early trial.
Simeprevir and Sofosbuvir Achieve High Cure Rates in Hep C Null-Responders
In an interim analysis, simeprevir and sofosbuvir showed high cure rates in those who had failed a hep C therapy and had mild to moderate fibrosis.
Dolutegravir Appears Superior to Raltegravir Among HIV Salvage Patients
Interim 24-week results from a Phase III study comparing the investigatory dolutegravir to raltegravir among HIV-positive individuals who have experienced treatment failure suggest that dolutegravir is superior at suppressing virus.
March 10, 2013
Hep C Treatment Helps Stop Cirrhosis Progression in Those Coinfected With HIV
Hep C treatment for those coinfected with HIV who have compensated cirrhosis helps prevent decompensated cirrhosis and lowers the risk of death.
March 08, 2013
Antiretrovials Reduce Cellular Inflammation Among Elite Controllers of HIV
Elite controllers of HIV experience a reduction in markers of chronic cellular inflammation when taking antiretrovirals.
March 07, 2013
For People With HIV, Livalo Lowers LDL Better Than Pravachol
Livalo (pitavastatin) better lowers LDL (“bad”) cholesterol in HIV-positive adults with high cholesterol than another drug in the same class, Pravachol. 
HIV Is Associated With Increased Heart Attack Risk
People with HIV have a 50 percent increased risk of heart attack compared with the general population
March 06, 2013
Four in Five People With HIV and Hep C on Faldaprevir Achieve Early Treatment Success
Interim results from a trial of the hep C drug faldaprevir, given to people coinfected with hep C and HIV, have shown an 80 percent early success rate.
March 05, 2013
Women's PrEP Trial Interventions Fail to Protect From HIV
A large trial of three different pre-exposure prophylaxis methods has failed to protect a large cohort of African women against HIV transmission.
FDA Updates the Labels of Intelence (Etravirine) and Prezista (Darunavir)
The U.S. Food and Drug Administration has approved changes to the labels for the antiretrovirals (ARVs) Intelence (etravirine) and Prezista (darunavir).
HIV May Inhibit the Ability to Recognize Facial Emotions
The effects of HIV appear to diminish the ability to recognize both fear and happiness in others' faces.
Used Consistently for Anal Sex, Condoms Prevent 7 in 10 HIV Infections
Using condoms all the time for anal sex cuts HIV transmission rates by 70 percent, while using them inconsistently ultimately provides no protection. 
March 04, 2013
Baby Born With HIV Is Functionally Cured
After being treated with meds for 18 months right after being born with HIV, a now 2-year-old child seems to be functionally cured of the virus.
Increased Cytokine Levels in Semen May Aid in HIV Transmission
The concentration of cytokines in the semen of HIV-positive men may be a crucial factor that determines the transmission during vaginal sex.
March 02, 2013
Hepatitis B Increases Risk of Death for Those Coinfected With Hep C and HIV
Hepatitis B virus infection raises the risk of death by 75 percent for those who are also coinfected with hepatitis C virus and HIV.
Syringes With Less 'Dead Space' May Reduce HIV and Hep C Transmission
Syringes designed to have less “dead space,” retaining less fluid after injection, could help stem the HIV and hepatitis C epidemics among drug users.
More Treatment News

Have news about HIV? Send press releases, news tips and other announcements to

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.